Healthcare Industry News:  protein biomarkers 

Diagnostics Personnel

 News Release - October 21, 2006

HistoRx Announces Resignation of CEO & Co-Founder Robert A. Curtis

NEW HAVEN, Conn., Oct. 21 (HSMN NewsFeed) -- HistoRx, Inc., a privately held company developing novel in vitro diagnostics for cancer and other diseases, announced today that Robert A. Curtis, PharmD, has submitted his resignation from his position as President and CEO, effective today. The HistoRx board has named Rana Gupta of Navigator Technology Ventures as interim CEO until a new President and CEO is named.

"My fundamental passion is guiding companies through their initial growth," said Dr. Curtis. "When I co-founded HistoRx in 2004 with Dr. David Rimm, Associate Professor of Pathology at Yale University, the company had some great technology and we had dreams of pioneering the companion diagnostic area. Since beginning operations 18 months ago, HistoRx has grown to 30 employees. During this time, I also recruited an outstanding management team to complement the founding team. The company has a significant number of research collaborations and product development agreements with pharmaceutical and biotechnology companies that provide substantial revenue. As a team, we have built a very strong company poised for substantial growth in the fast- advancing field of in vitro diagnostics. With initial goals accomplished, I plan to take some time off and address some personal issues. I am committed to working with the board and the management team during this transition, and I have utmost confidence in HistoRx's future success."

"On behalf of the Board, I would like to thank Bob for his services and for his efforts in overseeing the company's transition from a start-up to an emerging leader in the in vitro diagnostics arena," said Mr. Gupta. "His entrepreneurial drive since start-up has been relentless. HistoRx will miss Bob's expertise, creativity, and leadership, and we wish him all the best in his future endeavors."

Dr. Curtis will remain a member of the Board of Directors and an advisor to the company.

About HistoRx (

HistoRx is a leader in the development of new quantitative histopathology technology that provides exceptional measurement and localization of protein biomarkers to generate more precise, efficient, and cost-effective answers about the safety and effectiveness of new therapeutics in drug development and to provide the foundation for companion diagnostic tests. HistoRx services and products are based on the company's proprietary AQUA® technology, the first platform capable of measuring biomarker concentration with subcellular resolution in tissue sections. HistoRx services are used throughout basic biomedical research, preclinical studies, and clinical drug development, facilitating the efforts of pharmaceutical and biotechnology companies to improve efficiency and effectiveness across the drug development pipeline in bringing new targeted therapies for cancer and other diseases to the marketplace. HistoRx develops companion diagnostic products that are linked to our partners' drug candidates to predict therapeutic outcome and pursues internal programs to develop proprietary standard-of-care diagnostics that offer substantial improvements over existing immunohistochemistry-based tests.

Source: HistoRx

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.